23-24 Executive Committee Workplan – building on accomplishments listed in the 2022-2023 President’s Report

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | **Priority Area** | **COMPONENTS** | **Who** | **NEXT STEPS** |
| 1 | **Coalition for a TB Free CA** | Create and support a sustainable connection with organization representatives from those leading and serving disproportionately impacted communities. | Ryan Clary w/  Julie Higashi and  Judith | Suggested: Engage: businesses with high-risk group employees (Oracle, Apple, GeneTech, etc. 1st f/u to Cis; reach out to the employer to join/support TB Elimination), Immigrant rights organizations, LatinX L.A. health advocates, |
| 2 | **TB Prevention Funding** | This is a priority for the coalition. |  |  |
| 3 | **Communications**   1. World TB Day 2. Brochure field test 3. I.d. the most effective patient education   materials and make accessible on website | 1. Annual updates to Social Media plan and supporting ideas from LHJs and CTC 2. Flipbook Project (CA Human Resource Development-HRD) 3. Communications – HRD Review of materials available in 2022, making recommendations for use, making available in ctca.org/toolbox, and completing TB Flipbook development | Kim Otello  Ashley Randle  Cathy Miller | NEW CEO (Breathe CA), Jackie Cuen (patient advocate), SD: Alejandra Pena Velazquez  B) and C)+HRD: Rocio Agraz-Lara, Catherine Bender |
| 4 | **CA TB Meetings** | Oct 2-4 Conf with ½ day CITC on 10/4 April Spring TB Controllers Mtg  Use L.A. California Endowment in the future? 2024 Spring in Oakland? Fall 2024 SoCal, Spring 2025 Los Angeles, Fall 2025 Conf in Sacramento at the venue we gave up this time? | Ankita Kadakia and Eva Reeder | Set Jan. All TB Controllers Call Agenda  Figure out where and when to have Spring TB Controllers Mtg  Find venue for Fall 2024 in SoCal |
| 5 | **Drug Availability**  **Workgroup** | meet monthly to discuss challenges with TB drug availability and procurement in with CDPH and NTCA. Identify opportunities for action, Surveyed programs in California to assess challenges and perspectives on shortages and treatment options, modified survey to be implemented nationally | Sundari Mase  Scott Nabity | Commented on draft FDA guidance: “Notifying.  FDA of a Discontinuance or Interruption in Manufacturing of Finished Products or Active Pharmaceutical Ingredients Under Section 506C of the FD&C Act” |
| [/2023-07238/notification-of-a-permanent-](https://www.federalregister.gov/documents/2023/04/06/2023-07238/notification-of-a-permanent-discontinuance-or-interruption-in-manufacturing-under-section-506c-of) |
| [discontinuance-or-interruption-in-manufacturing-under-](https://www.federalregister.gov/documents/2023/04/06/2023-07238/notification-of-a-permanent-discontinuance-or-interruption-in-manufacturing-under-section-506c-of) |
|  |
|
| **6** | **Finance Committee:** | Proposes Conference Fee to the EC | Amit Chitnis, Secretary Treasurer; Eva Reeder, President-Elect; Ankita Kadakia, President | |
| 7 | **TB Patient Survivor Outreach and Engagement** | | Ankita Kadakia | Campaign of awareness to TB Controllers –At the Conference, registration table, August EC item: referral to survivor network during treatment counteract isolation. |
| 8 | **CA Guidelines**  1. CI close, CM next  2.Infectiousness, BCole  3. LTBI  4. HCP – Lots of questions coming at TB Controllers. 5. Adult Risk Assessment | 1. Guidelines Review Steering Committee  2. Review for CA specific differences once national guidelines are released  3. Keep only what is uniquely CA from update Melony and Ankita with Sundari  4. Look at current requirements – Individual and Workplace. Legislation clean up for TB testing for low-risk populations (occ health exposure testing) Who needs serial testing? Infection control staff at hospitals have testing at hire (positive, how many were treated?) | 1. Michael Joseph 2.Barbara Cole 3.Ankita and Melony 4.Judith  5. Ann Loeffler | 1. In process, EC for review in chunks not all at once  2.Review for what is unique to CA after national guidance is updated.  3.Needs a CA differences only lens applied to the update.  4. Focus to be on HCP Treatment of positives (with a risk? Or all positives) rather than serial testing as protective. |
| 9 | IGRA Cost Workgroup |  | Ankita Kadakia | SD: Catherine Bender, OC: Ron Daria, AC: Sonal Buhain |
| 10 | LTBI Treatment Access | Equity issue - Access to LTBI is a big issue even the cost of LTBI medications! |  |  |